This Article Full Text Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Aengevaeren, W. R. M. Articles by van der Werf, T. Search for Related Content PubMed PubMed Citation Articles by Aengevaeren, W. R. M. Articles by van der Werf, T. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information Angina Coronary Artery Disease

(Circulation. 1997;96:429-435.)
© 1997 American Heart Association, Inc.

Articles

Functional Evaluation of Lipid-Lowering Therapy by Pravastatin in the Regression Growth Evaluation Statin Study (REGRESS)

Wim R. M. Aengevaeren, MD; Gerard J. H. Uijen, PhD; J. Wouter Jukema, MD; Albert V. G. Bruschke, MD; ; Tjeerd van der Werf, MD

From the Department of Cardiology, University Hospital Nijmegen, and Interuniversitary Cardiology Institute the Netherlands (J.W.J., A.V.G.B.), Utrecht, the Netherlands.

Correspondence to W.R.M. Aengevaeren, Department of Cardiology, University Hospital Nijmegen, PO Box 9101, 6500 HB Nijmegen, Netherlands. E-mail w.aengevaeren{at}cardio.azn.nl

Background Lipid-lowering therapy during 2 years in the Regression Growth Evaluation Statin Study (REGRESS) was associated with less progression of coronary atherosclerosis in the pravastatin group compared with the placebo group. The effect of lipid-lowering therapy on the functional state of the coronary circulation is less well known. The purpose of this study was to evaluate this effect.

Methods and Results In a substudy of REGRESS, 69 patients were randomized to pravastatin or placebo. Thirty-seven of these patients were allocated to the medical management stratum. Quantitative coronary angiography, regional myocardial perfusion, exercise testing, and classification of angina pectoris were assessed at baseline and after 2 years of therapy. Regional myocardial perfusion was assessed by digital subtraction angiography after intracoronary papaverine with videodensitometric calculation of the hyperemic mean transit time (HMTT) of contrast. In the medical management stratum, regional myocardial perfusion was assessed in 31 regions in the pravastatin group and 25 regions in the placebo group. The change in HMTT in the pravastatin group was -0.18 seconds (-5%) and in the placebo group +0.52 seconds (+18%), a difference of 0.70 seconds (P=.004). The mean difference in change in classification of angina pectoris (scale, 1 to 4) between pravastatin and placebo was 0.7 (P=.03) in favor of the pravastatin-treated patients. The change in HMTT was correlated with the change in exercise time (r=-.65, P=.002).

Conclusions In patients with symptomatic coronary artery disease, treatment with the HMG-coenzyme A reductase inhibitor pravastatin during 2 years resulted in a preserved regional myocardial perfusion, whereas patients on placebo deteriorated. The classification of angina pectoris improved only in patients receiving pravastatin. In lipid-lowering therapy, the evaluation of myocardial perfusion by assessment of the HMTT reveals a combined measure of functional and structural changes in the coronary circulation.

Key Words: perfusion • exercise • coronary disease • angiography • lipids

This article has been cited by other articles:

				E Biagini, A F L Schinkel, J J Bax, V Rizzello, R T van Domburg, B J Krenning, M Bountioukos, C Pedone, E C Vourvouri, C Rapezzi, et al. Long term outcome in patients with silent versus symptomatic ischaemia during dobutamine stress echocardiography Heart, June 1, 2005; 91(6): 737 - 742. [Abstract] [Full Text] [PDF]

				P.W Serruys and J Aoki Therapeutic options for patients with chronic myocardial ischaemia Eur. Heart J. Suppl., September 1, 2004; 6(suppl_E): E2 - E11. [Abstract] [Full Text]

				J. S. Hooper and A. J. Busti Ranolazine as Add-on Therapy for Patients With Severe Chronic Angina JAMA, April 28, 2004; 291(16): 1959 - 1959. [Full Text] [PDF]

				V. S. Monroe, R. A. Kerensky, E. Rivera, K. M. Smith, and C. J. Pepine Pharmacologic plaque passivation for the reduction of recurrent cardiac events in acute coronary syndromes J. Am. Coll. Cardiol., February 19, 2003; 41(4_Suppl_S): 23S - 30S. [Abstract] [Full Text] [PDF]

				References Circulation, December 17, 2002; 106(25): 3373 - 3421. [Full Text]

				D. Pillay, Z. A. Abdul Hamid, D. Pillay, and Z. A. Abdul Hamid Spontaneous Regression of Ostial Coronary Artery Lesion Asian Cardiovasc Thorac Ann, December 1, 2000; 8(4): 364 - 365. [Abstract] [Full Text] [PDF]

				K. K. Koh Effects of statins on vascular wall: vasomotor function, inflammation, and plaque stability Cardiovasc Res, September 1, 2000; 47(4): 648 - 657. [Abstract] [Full Text] [PDF]

				T. J. Anderson Assessment and treatment of endothelial dysfunction in humans J. Am. Coll. Cardiol., September 1, 1999; 34(3): 631 - 638. [Full Text] [PDF]

				H. Drexler Nitric oxide and coronary endothelial dysfunction in humans Cardiovasc Res, August 15, 1999; 43(3): 572 - 579. [Full Text] [PDF]

				R. S. Rosenson and C. C. Tangney Antiatherothrombotic Properties of Statins: Implications for Cardiovascular Event Reduction JAMA, May 27, 1998; 279(20): 1643 - 1650. [Abstract] [Full Text] [PDF]

				F.-C. Schoebel, T. W. Jax, B.-E. Strauer, M. Leschke, and W. R. M. A. A. J. v. B. A. H. Z. J. W. J. A. V. G. van der Werf Functional Evaluation of Lipid-Lowering Therapy by Pravastatin • Response Circulation, May 12, 1998; 97(18): 1874 - 1875. [Full Text]